for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioMarin Pharmaceutical Inc.

BMRN.O

Latest Trade

83.05USD

Change

-0.65(-0.78%)

Volume

756,213

Today's Range

82.82

 - 

85.38

52 Week Range

71.59

 - 

92.17

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
83.70
Open
84.01
Volume
756,213
3M AVG Volume
30.81
Today's High
85.38
Today's Low
82.82
52 Week High
92.17
52 Week Low
71.59
Shares Out (MIL)
183.59
Market Cap (MIL)
15,366.77
Forward P/E
-229.76
Dividend (Yield %)
--

Next Event

Q4 2021 Biomarin Pharmaceutical Inc Earnings Release

Latest Developments

More

Biomarin And Skyline Therapeutics Announce Strategic Collaboration

Biomarin Receives FDA Approval For Voxzogo For Injection

FDA Approves First Drug To Improve Growth In Children With Most Common Form Of Dwarfism

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).

Industry

Biotechnology & Drugs

Contact Info

105 Digital Dr

NOVATO, CA

94949-8703

United States

+1.415.5066700

https://www.biomarin.com/

Executive Leadership

Jean-Jacques Bienaime

Chairman of the Board, Chief Executive Officer

Brian R. Mueller

Chief Financial Officer, Executive Vice President

Henry J. Fuchs

President - Worldwide Research & Development

C. Greg Guyer

Chief Technical Officer, Executive Vice President of Global Manufacturing, Technical Operations

G. Eric Davis

Executive Vice President, General Counsel, Secretary

Key Stats

1.71 mean rating - 21 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.5K

2019

1.7K

2020

1.9K

2021(E)

1.8K
EPS (USD)

2018

-0.440

2019

-0.130

2020

4.530

2021(E)

-0.364
Price To Earnings (TTM)
--
Price To Sales (TTM)
8.31
Price To Book (MRQ)
3.60
Price To Cash Flow (TTM)
240.44
Total Debt To Equity (MRQ)
25.27
LT Debt To Equity (MRQ)
25.27
Return on Investment (TTM)
-0.85
Return on Equity (TTM)
-0.75

Latest News

Latest News

BioMarin drug becomes first U.S. approved therapy for dwarfism

BioMarin Pharmaceutical Inc's once-daily injection for children with the most common type of dwarfism received clearance from the U.S. health regulator on Friday, making it the first approved therapy for achondroplasia in the country.

Biomarin's drug wins Europe's first approval for type of dwarfism

U.S.-based Biomarin Pharmaceutical Inc's treatment for one of the most common forms of dwarfism received clearance from the European Commission, becoming the first therapy to get an approval in the region for achondroplasia.

U.S. FDA rejects BioMarin hemophilia A gene therapy, shares dive

The U.S. Food and Drug Administration rejected BioMarin Pharmaceutical Inc's gene therapy for bleeding disorder hemophilia A citing the need for longer-term data, the drugmaker said on Wednesday, potentially pushing any approval out to 2022.

U.S. FDA declines to approve Biomarin's gene therapy for bleeding disorder

The U.S. Food and Drug Administration has declined to approve BioMarin Pharmaceutical Inc's gene therapy for bleeding disorder hemophilia A, citing the need for two-year data on the therapy, the drugmaker said on Wednesday.

BRIEF-BioMarin Promotes Company Veteran Brian Mueller To Executive Vice President, CFO

* BIOMARIN PROMOTES COMPANY VETERAN, BRIAN R. MUELLER, TO EXECUTIVE VICE PRESIDENT, CFO Source text for Eikon: Further company coverage:

BRIEF-BioMarin Provides New Data from Study Of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

* BIOMARIN PROVIDES ADDITIONAL DATA FROM RECENT 4 YEAR UPDATE OF ONGOING PHASE 1/2 STUDY OF VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY FOR SEVERE HEMOPHILIA A IN LATE-BREAKING ORAL PRESENTATION AT WORLD FEDERATION OF HEMOPHILIA VIRTUAL SUMMIT Source text for Eikon: Further...

BRIEF-Biomarin Announces Pricing Of Upsized $550 Mln Senior Subordinated Convertible Notes Offering

* BIOMARIN ANNOUNCES PRICING OF UPSIZED $550 MILLION SENIOR SUBORDINATED CONVERTIBLE NOTES OFFERING

BRIEF-Biomarin Reports Proposed Private Offering Of $500 Million Of Senior Subordinated Convertible Notes

* BIOMARIN ANNOUNCES PROPOSED PRIVATE OFFERING OF $500 MILLION OF SENIOR SUBORDINATED CONVERTIBLE NOTES

BRIEF-Biomarin Says Extends Gene Therapy Leadership With Dinaqor In Preclinical Collaboration And License Agreement To Develop Gene Therapies For Rare Genetic Cardiomyopathies

* BIOMARIN EXTENDS GENE THERAPY LEADERSHIP WITH DINAQOR IN A PRECLINICAL COLLABORATION AND LICENSE AGREEMENT TO DEVELOP GENE THERAPIES FOR RARE GENETIC CARDIOMYOPATHIES

BRIEF-Biomarin Reports Q1 2020 Total Revenue Growth Of 25% To $502 Mln

* BIOMARIN ANNOUNCES FIRST QUARTER 2020 TOTAL REVENUE GROWTH OF 25% TO $502 MILLION

BRIEF-BioMarin Plans Regulatory Submissions For Marketing Authorization Of Vosoritide

* BIOMARIN PLANS REGULATORY SUBMISSIONS FOR MARKETING AUTHORIZATION OF VOSORITIDE TO TREAT CHILDREN WITH ACHONDROPLASIA IN 3Q 2020 IN BOTH US AND EUROPE Source text for Eikon: Further company coverage:

BRIEF-Biomarin Says For Full-Year 2020 Expect For First Time To Be Profitable On GAAP Basis

* BIOMARIN ANNOUNCES FOURTH QUARTER AND RECORD FULL-YEAR 2019 FINANCIAL RESULTS

Sanofi ex-employee can join hemophilia treatment rival BioMarin - judge

Sanofi SA's Genzyme unit cannot block a former employee from joining BioMarin Pharmaceutical Inc, where he would help launch a gene therapy treatment for hemophilia that would compete with a drug his ex-employer markets, a Massachusetts judge has ruled.

CORRECTED-BRIEF-Biomarin Pharmaceutical Reports Qtrly Earnings Per Share Of $0.30 (Oct.23)

* Q3 REVENUE $461.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $454.5 MILLION

BioMarin says data shows hemophilia gene therapy effects could wane

BioMarin Pharmaceutical Inc said on Tuesday early trial data for its gene therapy for hemophilia A suggested the one-time infusion's effect on some patients' bleeding disorders would last eight years.

BRIEF-BioMarin Says Payers Unlikely To Accept Price Equivalent To Over 5 Years Of Standard Treatment Costs For Hemophilia Gene Therapy

* BIOMARIN CEO SAYS BELIEVES ONCE HEMOPHILIA GENE THERAPY IS APPROVED CO WILL BE IN 'PRETTY GOOD SHAPE' FOR DISCUSSION ON PRICE WITH PAYERS BASED ON FIVE YEARS OF COSTS, SIMILAR TO NOVARTIS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up